18 Commerce Way
Replimune is developing novel, proprietary oncolytic immunotherapies intended to improve both the direct anti-tumor effects of selective virus replication and the potency of the immune response to the tumor antigens released. Replimune intends to progress these rapidly through clinical trials and to combine these with checkpoint blockade at an early stage of clinical development.
Executive Chairman & Director: Philip Astley-Sparke
CEO & Director: Robert Coffin, Ph.D.
COO: Colin Love, Ph.D.
CBO: Pamela Esposito, Ph.D.
CMO: Howard Kaufman, M.D.
VP, Clinical Development: Susan Doleman
Sr. VP of Regulatory Affairs and QA: Anne Marie Woodland
VP, Research: Suzanne Thomas, Ph.D.
Please click here for Replimune's science.
30 articles with Replimune
Replimune Group, Inc., a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, announced the pricing of its public offering of 3,678,031 shares of its common stock at a public offering price of $13.61 per share.
Replimune Group, Inc., a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, announced a proposed public offering of up to 5,000,000 shares of its common stock.
Replimune Presents Initial Clinical Data with RP1 that Strongly Supports Expansion of Clinical Programs in Melanoma and Cutaneous Squamous Cell Carcinoma (CSCC)
Data demonstrate RP1 alone and combined with Opdivo® is well tolerated with anti-tumor efficacy in target tumor types
Replimune Announces First Patient Enrolled in Phase 1 Clinical Trial of RP2 Alone and in Combination with Opdivo® in Advanced Cancer PatientsReplimune’s second product candidate to enter the clinic is an Immulytic™ that expresses an anti-CTLA-4
Replimune Group Inc., a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic platform, announced that the company has enrolled the first patient in its Phase 1 clinical trial of RP2.
First patient enrolled in registration-directed Phase 2 clinical trial of RP1 in combination with Regeneron and Sanofi’s Libtayo® in CSCC
Most of the IPOs that occurred in the Bay State have been well-documented by BioSpace. But, with a new calendar year upon us, it’s a good idea to look back at a banner year of capitalization that may not repeat when January rolls around. With the turn of the year only days away, BioSpace takes a ...
One year after Vivek Ramaswamy launched Urovant Sciences to develop urological therapies, the company is now seeking $150 million from an initial public offering.
It’s been a big year so far for activity in the U.S. biopharma market—record IPOs and plenty of big acquisitions. But things may be heating up in Europe as well.
Dieter brings a wealth of strategic and operational experience to Replimune that will strengthen the perspectives of the Board and guide the Company at this exciting time.
Replimune Announces First Patients Dosed in a Phase I/II Clinical Trial of its RP1 Oncolytic Immunotherapy in Patients With Advanced Solid Tumors
The Phase I/II clinical trial is designed in two parts to assess the safety, tolerability and preliminary efficacy of RP1 alone and in combination with anti-PD1 therapy.